Veracyte, Inc.: The Global Diagnostics Company Leading the Charge in Genomic Sequencing and Cancer Diagnosis Veracyte, Inc. is a transformative diagnostics company with a global presence, offering a range of cutting-edge tests for diagnosing various types of cancer, including prostate, breast, lung, interstitial lung disease, colon cancer, and lymphoma subtyping. The company's most popular tests include the Afirma Genomic Sequencing Classifier, Decipher Prostate Biopsy and Radical Prostatectomy, Prosigna Breast Cancer Assay, Percepta Nasal Swab Test, Envisia Genomic Classifier, and Immunoscore Colon Cancer test. By leveraging cutting-edge genomic sequencing and deep learning, Veracyte's tests can identify cancerous cells more accurately and with higher precision than traditional methods. Furthermore, the company is at the forefront of developing innovative cancer treatments, with technology licensing and collaboration arrangements with industry heavyweights Johnson & Johnson, Acerta Pharma, and CareDx. Veracyte, Inc. was founded in 2006, under the name of Calderome, Inc., and has since grown to become a leading name in the diagnostics industry with headquarters based in South San Francisco, California. The company is currently developing the Percepta Genomic Atlas to help inform lung cancer treatment decisions, Envisia Classifier, the nCounter analysis system, and LymphMark, a lymphoma subtyping test. As healthcare industries around the world continue to adopt more precise, personalized treatment options for cancer, Veracyte, Inc. is well-positioned to emerge as a key player in this fast-evolving landscape.
Veracyte's ticker is VCYT
The company's shares trade on the NASDAQ stock exchange
They are based in South San Francisco, California
There are 201-500 employees working at Veracyte
It is veracyte.com/who-we-are/about-us
Veracyte is in the Healthcare sector
Veracyte is in the Biotechnology industry
The following five companies are Veracyte's industry peers: